SLC16A11抗体

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Rat liver tissue lysate, Primary antibody: P05293(SLC16A11 Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 3 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P05293(SLC16A11 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

The SLC16A11 antibody is a research tool designed to target the solute carrier family 16 member 11 (SLC16A11), a transmembrane protein belonging to the monocarboxylate transporter (MCT) family. SLC16A11 is encoded by the *SLC16A11* gene, located on human chromosome 17p13. It is primarily expressed in the liver, kidney, and pancreas. While its exact physiological role remains under investigation, SLC16A11 is implicated in transporting small metabolites, such as monocarboxylates, across cellular membranes. Notably, genetic variants in *SLC16A11* have been linked to an increased risk of type 2 diabetes (T2D) through genome-wide association studies (GWAS), particularly in Latin American populations. These variants may disrupt protein function, contributing to impaired lipid metabolism and insulin secretion.

Antibodies against SLC16A11 are critical for elucidating its expression patterns, subcellular localization, and interaction partners. They are commonly used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to study protein levels in tissues or cell lines. Due to SLC16A11's hydrophobic transmembrane domains, generating specific antibodies can be challenging, requiring careful validation to ensure target specificity. Research utilizing these antibodies has helped uncover SLC16A11's potential role in metabolic diseases, offering insights into therapeutic strategies for T2D. However, functional studies remain ongoing to fully clarify its mechanisms in health and disease.